
Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence future clinical practices and shared decision-making models, while identifying key areas for further research and collaboration to improve patient outcomes.
Video content above is prompted by the following:
Evolving Treatment Paradigms for Hematologic Malignancies in Community Oncology Settings
January 11th 2026In an interview during ASH 2025, Ontada's Ira Zackon, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.
Read More
Evolving Treatment Paradigms for Hematologic Malignancies in Community Oncology Settings
January 11th 2026In an interview during ASH 2025, Ontada's Ira Zackon, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.
Read More
2 Commerce Drive
Cranbury, NJ 08512